Revelation Biosciences Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 31 Mar 2026
Net Income -$9.9MTTM through 31 Mar 2026
Free Cash Flow -$8.8MTTM through 31 Mar 2026
Margins
| Current |
|---|
Returns
-76.0%ROE
-65.6%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio10.02x
Net Debt-$14.1Mnet cash position
Cash & Equivalents$14.1M
Quality Metrics
Earnings-Beat Rate25.0%
Dividend
No dividend
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Gemini Development | $0 | View detailsThe company has reached an agreement with the FDA on a single adaptive Phase 2/3 study design for Gemini in AKI, planned to commence in late 2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.